BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 2465227)

  • 1. Haemostasis and oral contraceptives.
    Farag A; Bottoms SF; Mammen EF; Hosni M; Ali A
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(3):340-5. PubMed ID: 2465227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in haemostatic variables induced by oral contraceptives containing 50 micrograms or 30 micrograms oestrogen: absence of dose-dependent effect on PAI-1 activity.
    Scarabin PY; Plu-Bureau G; Zitoun D; Bara L; Guize L; Samama MM
    Thromb Haemost; 1995 Sep; 74(3):928-32. PubMed ID: 8571323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral contraceptives and the hemostatic system.
    Farag AM; Bottoms SF; Mammen EF; Hosni MA; Ali AA; Moghissi KS
    Obstet Gynecol; 1988 Apr; 71(4):584-8. PubMed ID: 3353050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemostatic effects of oral contraceptives in women who developed deep-vein thrombosis while using oral contraceptives.
    Bloemenkamp KW; Rosendaal FR; Helmerhorst FM; Koster T; Bertina RM; Vandenbroucke JP
    Thromb Haemost; 1998 Sep; 80(3):382-7. PubMed ID: 9759614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance to activated protein C in women using oral contraceptives.
    Spannagl M; Dick A; Assmann A; Heinemann L; Schramm W
    Semin Thromb Hemost; 1998; 24(5):423-30. PubMed ID: 9834008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased heparin cofactor II levels in women taking oral contraceptives.
    Toulon P; Bardin JM; Blumenfeld N
    Thromb Haemost; 1990 Nov; 64(3):365-8. PubMed ID: 2096488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus.
    Petersen KR
    Dan Med Bull; 2002 Feb; 49(1):43-60. PubMed ID: 11894723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cardiovascular risks of oral contraceptives: dose-response relationship].
    Kelleher CC
    Contracept Fertil Sex (Paris); 1991 Apr; 19(4):285-8. PubMed ID: 12343220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral contraceptive risks: a realistic appraisal.
    Bressler R; Durand JL
    Drug Ther (NY); 1979 Oct; 9(10):81-95. PubMed ID: 12279276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of thrombotic risk factors when oral contraceptives are prescribed. A control-only study.
    Lidegaard O
    Acta Obstet Gynecol Scand; 1997 Mar; 76(3):252-60. PubMed ID: 9093141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective screening for the Factor V Leiden mutation: is it advisable prior to the prescription of oral contraceptives?
    Schambeck CM; Schwender S; Haubitz I; Geisen UE; Grossmann RE; Keller F
    Thromb Haemost; 1997 Dec; 78(6):1480-3. PubMed ID: 9423798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of oestrogen dose on whole blood platelet activation in women taking new low dose oral contraceptives.
    Norris LA; Bonnar J
    Thromb Haemost; 1994 Dec; 72(6):926-30. PubMed ID: 7740465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The case for a lower dose pill. Assessing the impact of estrogen dose.
    Brown S; Cropfield O
    ORGYN; 1995; (2):36-9. PubMed ID: 12319251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Royal College of General Practitioners' Oral Contraception Study: some recent observations.
    Kay CR
    Clin Obstet Gynaecol; 1984 Dec; 11(3):759-86. PubMed ID: 6509858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weighing the evidence on the pill and breast cancer.
    Johnson JH
    Fam Plann Perspect; 1989; 21(2):89-92. PubMed ID: 2653859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risks of oral contraceptive use in women over 35.
    Stenchever MA
    J Reprod Med; 1993 Dec; 38(12 Suppl):1030-5. PubMed ID: 8120860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated plasma fibrinogen and increased fibrin turnover among healthy women who both smoke and use low-dose oral contraceptives--a preliminary report.
    Scarabin PY; Vissac AM; Kirzin JM; Bourgeat P; Amiral J; Agher R; Guize L
    Thromb Haemost; 1999 Sep; 82(3):1112-6. PubMed ID: 10494773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The misunderstood pill: thirty years of testing and development have reduced pill's major, minor side effects.
    United States. Centers for Disease Control CDC. Advisory Committee on Immunization Practices
    Netw Res Triangle Park N C; 1986; 7(4):1-5. PubMed ID: 12341093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombotic risk factors and oral contraception.
    Bokarewa MI; Falk G; Sten-Linder M; Egberg N; Blombäck M; Bremme K
    J Lab Clin Med; 1995 Sep; 126(3):294-8. PubMed ID: 7665978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Significance of hereditary thrombophilia for risk of thrombosis with oral contraceptives].
    Bauersachs R; Lindhoff-Last E; Ehrly AM; Kuhl H
    Zentralbl Gynakol; 1996; 118(5):262-70. PubMed ID: 8701622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.